Potential Therapeutic Targets of B7 Family in Colorectal Cancer

Front Immunol. 2020 May 5:11:681. doi: 10.3389/fimmu.2020.00681. eCollection 2020.

Abstract

Programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway blockade has impressively benefited cancer patients with a wide spectrum of tumors. However, its efficacy in colorectal cancer (CRC) is modest, and only a small subset of patients benefits from approved checkpoint inhibitors. Newer checkpoints that target additional immunomodulatory pathways are becoming necessary to activate durable antitumor immune responses in patients with CRC. In this review, we evaluated the mRNA expression of all 10 reported B7 family members in human CRC by retrieving and analyzing the TCGA database and reviewed the current understanding of the top three B7 family checkpoint molecules (B7-H3, VISTA, and HHLA2) with the highest mRNA expression, introducing them as putative therapeutic targets in CRC.

Keywords: B7-H3; HHLA2; VISTA; colorectal cancer; immune checkpoint.

Publication types

  • Review

MeSH terms

  • Animals
  • B7 Antigens / antagonists & inhibitors
  • B7 Antigens / genetics*
  • B7 Antigens / metabolism
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / genetics
  • Colorectal Neoplasms / immunology*
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Immunoglobulins / genetics*
  • Immunoglobulins / metabolism
  • Immunotherapy / methods*
  • Mice
  • Molecular Targeted Therapy / methods*
  • RNA, Messenger / genetics
  • Tumor Microenvironment / genetics
  • Tumor Microenvironment / immunology

Substances

  • B7 Antigens
  • CD276 protein, human
  • HHLA2 protein, human
  • Immune Checkpoint Inhibitors
  • Immunoglobulins
  • RNA, Messenger
  • VSIR protein, human